CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY ® and Regeneron's Veloci-Bi ® platforms -